---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-240237"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2025-10-15T23:59:59+00:00"
generated_at: "2026-05-17T03:44:28.697077+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spyre Therapeutics raises ~$316M in public offering of 17M shares at $18.50

## Summary
- Sold 14,864,865 shares at $18.50; underwriters exercised option for 2,229,729 additional shares.
- Gross proceeds of approximately $316.2 million before underwriting discounts and expenses.
- Net proceeds to fund IBD and rheumatic disease programs, including clinical trials and Phase 3 readiness.
- Underwriters include Jefferies, TD Securities, Leerink Partners, and Stifel; offering closed Oct 15, 2025.
- Offering was made under existing effective shelf registration statement (File No. 333-285341).

## SEC filing metadata
- accession: 0001193125-25-240237
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2025-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312525240237/0001193125-25-240237-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312525240237/d40269d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-240237
- JSON: https://secwatch.observer/filing/0001193125-25-240237.json
- Plain text: https://secwatch.observer/filing/0001193125-25-240237.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.